| Identification | Back Directory | [Name]
ALA-SER-THR-THR-THR-ASN-TYR-THR ACETATE | [CAS]
106362-32-7 | [Synonyms]
ALA-SER-THR-THR-THR-ASN-TYR-THR ACETATE
Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr acetate salt
L-Threonine, L-alanyl-L-seryl-L-threonyl-L-threonyl-L-threonyl-L-asparaginyl-L-tyrosyl-
L-Threonine, N-(N-(N2-(N-(N-(N-(N-L-alanyl-L-seryl)-L-thronyl)-L-threonyl)-L-threonyl)-L-asparaginyl)-L-tyrosyl)- | [Molecular Formula]
C35H55N9O16 | [MDL Number]
MFCD00076837 | [MOL File]
106362-32-7.mol | [Molecular Weight]
857.86 |
| Chemical Properties | Back Directory | [Boiling point ]
1499.5±65.0 °C(Predicted) | [density ]
1.432±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
3.21±0.10(Predicted) | [color ]
White to off-white | [Sequence]
Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr |
| Hazard Information | Back Directory | [Uses]
Peptide T is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a ligand for the CD4 receptor and prevents binding of HIV to the CD4 receptor. | [in vivo]
Peptide T is administered subcutaneously at different doses and phases of the experimental autoimmune encephalomyelitis (EAE) disease, but Peptide T neither prevents nor ameliorates EAE[4]. | [IC 50]
HIV-1 | [References]
[1] Ruff MR, et al. Peptide T[4-8] is core HIV envelope sequence required for CD4 receptor attachment. Lancet. 1987 Sep 26;2(8561):751. DOI:10.1016/s0140-6736(87)91120-2
[2] Ruff MR, et al. Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5). Antiviral Res. 2001 Oct;52(1):63-75. DOI:10.1016/s0166-3542(01)00163-2
[3] Raychaudhuri SP, et al. Immunomodulatory effects of peptide T on Th 1/Th 2 cytokines. Int J Immunopharmacol. 1999 Sep;21(9):609-15. DOI:10.1016/s0192-0561(99)00041-7
[4] Sáez-Torres I, et al. Peptide T does not ameliorate experimental autoimmune encephalomyelitis (EAE) in Lewis rats. Clin Exp Immunol. 2000 Jul;121(1):151-6. DOI:10.1046/j.1365-2249.2000.01259.x |
|
|